Poor
Not Aligned
Patient Risk:
High
Summary
Many safety and interaction claims are not supported by the provided labeling excerpts, including a specific statin–myopathy risk and multiple specific food/supplement interaction claims, plus an unsupported dosing-frequency statement. Some indication and general bleeding-risk claims are supported, but overall label-faithfulness is poor.
Category Scores
Accurate Statements
Vascepa reduces the risk of cardiovascular events in patients with high triglycerides.
Supported by Indications and Usage: reduction of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglycerides (≥150 mg/dL) with specified cardiovascular disease or diabetes plus risk factors (1 INDICATIONS AND USAGE).
Vascepa is available in capsule form.
Supported by Dosage Forms and Strengths: “VASCEPA capsules are supplied as…” (3 DOSAGE FORMS AND STRENGTHS).
Taking Vascepa with warfarin may increase the risk of bleeding.
Supported by Bleeding warning noting increased incidence with concomitant antithrombotic medications such as warfarin (5 WARNINGS AND PRECAUTIONS; also referenced in 7 DRUG INTERACTIONS section context).
Taking Vascepa with aspirin may increase the risk of bleeding.
Supported: bleeding incidence is greater with concomitant antithrombotic medications such as aspirin (5 WARNINGS AND PRECAUTIONS).
Taking Vascepa with clopidogrel (Plavix) may increase the risk of bleeding.
Supported: bleeding incidence is greater with concomitant antithrombotic medications such as clopidogrel (5 WARNINGS AND PRECAUTIONS).
Unsupported Statements
Vascepa is typically taken once or twice daily.
No dosing frequency (e.g., once/twice daily) is present in the provided label excerpts (2 DOSAGE AND ADMINISTRATION section text not provided; frequency claim not supported by supplied text).
Combining Vascepa with statins may increase the risk of muscle damage (myopathy).
No statin–myopathy/muscle damage interaction is supported by the provided label excerpts.
Combining Vascepa with cholestyramine may reduce the absorption of icosapent ethyl, leading to reduced efficacy.
No cholestyramine interaction, absorption statement, or efficacy reduction is supported by the provided label excerpts.
Taking Vascepa with orlistat may reduce the absorption of icosapent ethyl, leading to reduced efficacy.
No orlistat interaction, absorption statement, or efficacy reduction is supported by the provided label excerpts.
Combining Vascepa with flaxseed oil may increase the risk of bleeding.
No flaxseed oil interaction/bleeding risk is supported by the provided label excerpts.
Eating fatty foods with Vascepa may reduce the absorption of icosapent ethyl, leading to reduced efficacy.
No “fatty foods” absorption/efficacy interaction is supported by the provided label excerpts.
Taking Vascepa with other omega-3 fatty acid supplements may increase the risk of bleeding.
While the label excerpt discusses omega-3 fatty acids prolonging bleeding time and monitoring with concomitant anticoagulants/antiplatelet agents, it does not specifically support the blanket statement that taking “other omega-3 fatty acid supplements” increases bleeding risk as stated.
Contradictions
Important Omissions
Dose and administration details (including exact dosing frequency, titration, and administration instructions) are not evaluated here because the provided label excerpts for 2 DOSAGE AND ADMINISTRATION do not include the actual dosing instructions text; an unsupported frequency claim was made anyway.
Importance:
Moderate
The claim “Vascepa inhibits the production of triglycerides in the liver” is only partially supported as phrased; the label excerpt describes mechanisms including reduced lipogenesis and effects on hepatic VLDL-TG synthesis/secretion rather than a direct, simplified “inhibits triglyceride production” statement. This is an omission of label-accurate nuance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple unsupported interaction and dosing claims were made, including a specific myopathy risk with statins and several specific absorption/efficacy interaction claims, plus an unsupported dosing-frequency statement. These inaccuracies could mislead clinical decision-making and patient counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpts, especially drug interactions (statins/myopathy, cholestyramine, orlistat, flaxseed oil, fatty foods, broad omega-3 supplement bleeding risk) and dosing frequency (once/twice daily).
Suggested Improvement
Remove unsupported dosing-frequency and interaction claims. Rephrase bleeding-risk statements to match the provided label language (increased bleeding incidence with concomitant antithrombotic medications such as aspirin, clopidogrel, warfarin; monitor for bleeding when combined with anticoagulants/antiplatelet agents). Ensure mechanistic claims reflect the label’s described mechanisms (e.g., reduced lipogenesis/inhibition of DGAT; hepatic VLDL-TG synthesis/secretion) rather than simplified direct assertions.